Metadata record for the manuscript: Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: A phase II and biomarker study

Summary This metadata record provides details of the data supporting the claims of the related manuscript: “Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: A phase II and biomarker study”. The related study was a single-arm phase II study which investigated the efficacy and safety of cabozantinib combined with nivolumab in metastatic triple-negative breast cancer (mTNBC). Type of data: whole exome sequencing; linked genotype and phenotype data; genomic profiling; open-label, single-arm, single center phase II study; clinical data Subject of data: Homo sapiens Sample size: 18 Population characteristics: Eligible patients had histologically or cytologically confirmed invasive breast cancer with metastatic disease that was measurable per RECIST 1.1 . Tumors were required to be estrogen receptor (ER)-negative and progesterone receptor-negative, defined as Trial registration number: NCT03316586 Data access The whole exome and transcriptome data have been deposited in the dbGaP repository under accession https://identifiers.org/dbgap:phs002419.v1.p1. In order to protect patient privacy, these data are controlled access. Details of how to request access can be found on the dbGaP landing page. The genomic profiling data are in Supplementary Tables 2 and 4. The supplementary tables of the related article are openly available as part of this figshare data record (as well as via the supplementary materials of the related article) in the file ‘Supplementary Data 1_5-14-21.xlsx’. Corresponding author(s) for this study Sara M. Tolaney, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Tel: [phone]. [e-mail] Study approval The Dana-Farber Cancer Institute institutional review board approved the study and written informed consent from all trial participants was provided before study entry. The study was monitored by the Data Safety Monitoring Board of the Dana-Farber/Harvard Cancer Center.